Turn Therapeutics Shares Surge on Positive Interim Phase 2 Data for Atopic Dermatitis Drug GX-03

Turn Therapeutics reported positive interim Phase 2 trial results for its atopic dermatitis candidate GX-03 on June 2, 2026, sending shares sharply higher in early trading. The company said the drug met its primary endpoint, demonstrating a statistically significant reduction in eczema severity scores versus placebo after four weeks of treatment. Specific efficacy data and safety outcomes were not disclosed in the initial release, but management described the results as “clinically meaningful.” The study enrolled patients with moderate-to-severe atopic dermatitis, a chronic inflammatory skin condition affecting an estimated 16 million adults in the U.S. GX-03 is a topical formulation designed to repair the skin barrier and reduce inflammation without the side effects associated with steroid creams or systemic biologics. Turn Therapeutics plans to present full data at a medical conference later this year and is in discussions with regulators to design a pivotal Phase 3 program. Shares rose as much as 18% in pre-market activity, reflecting investor optimism for a potential new therapy in the competitive dermatology market, which includes blockbuster drugs like Sanofi’s Dupixent.